FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
arGEN-X creates novel, antibody-based medicines using the SIMPLE Antibody™ platform to generate leads of unparalleled functional diversity, allowing optimal selection of mAb candidates. The proprietary NHance™ half-life extension technology also allows tailoring of antibodies for attractive dosing regimes, patient convenience and pharmacoeconomics. arGEN-X has demonstrated its ability to provide first and best in class biopharmaceuticals in internal and partnered therapeutic antibody programs.
arGEN-X is an emerging force in human antibody therapeutics.
Its SIMPLE Antibody™ platform generates an unparalleled functional diversity of human antibody leads which routinely exhibit gold standard affinities, potencies and expression levels.
The SIMPLE Antibody™ engine can be effectively applied to most protein classes, including cell surface targets and complex receptors. Through the efficient isolation of unique functional clones, product candidates with desirable therapeutic properties are rapidly identiﬁed. This approach maximizes the chance of success in therapeutic product development.
arGEN-X is building a portfolio of novel preclinical programs addressing multiple therapeutic areas. Its lead program is pursuing a target implicated in autoimmunity, while two further discovery programs in bone disease and oncology are underway.
The SIMPLE Antibody™ technology is covered by broad composition of matter and process patent claims. arGEN-X beneﬁts both from freedom to operate and absence of any gatekeeping restrictions on targets.